Clinical outcome in recurrent and/or metastatic head and neck cancer patients after discontinuation of nivolumab monotherapy due to immune-related adverse events

Head and Neck Cancer
18/08/2020

Acta Otolaryngol. 2020 Aug 18:1-6. doi: 10.1080/00016489.2020.1807601. Online ahead of print.

ABSTRACT

BACKGROUND: Significant immune-related adverse events (irAEs) requiring therapy discontinuation sometimes occur. The influence of discontinuation on disease control after an irAE is unclear.

OBJECTIVES: The aim of this study was to investigate whether or not patients continued to show a response or durable disease control even after stopping therapy following an irAE.

MATERIAL AND METHODS: The response after nivolumab monotherapy discontinuation was examined for 14 patients in whom therapy was stopped without progression.

RESULTS: The best response was CR in 5 (36%) patients, PR in 8 (57%) patients and SD in 1 (7%) patient. The estimated 1-year overall and progression-free survival rates were 92.9% and 78.6%, respectively. The best response during nivolumab therapy in patients who developed PD was CR in 0 of 5 patients (0%), PR in 3 of 8 patients (38%) and SD in 1 patient (100%). Patients obtaining CR tended to have a lower risk of PD than those with PR or SD.

CONCLUSIONS AND SIGNIFICANCE: Patients with CR status may continue to show a response or durable disease control even after stopping therapy due to an irAE.